Trim 35-40% of MDT at ~$86, anchor 60-65% core at $84.00 daily-close stop; no puts; re-engage on $89.50 bull trigger or Q2 FY27 print
Underweight with 35-40% trim at market, anchored at $84.00 daily-close stop, no puts, $89.50 bull trigger, Q2 FY27 print as mandatory re-evaluation. The synthesis corrects the trader's Sell (overweighting technical signal, unlimited downside on 47-year Aristocrat) and the Conservative's Hold (underweighting confirmed deterioration stack). The retained core maintains 3.3% dividend carry and Q2 FY27 optionality while the trim removes bulk of breakdown risk. Key inputs absorbed: 9/28 lesson (trim-on-deterioration not wait-for-confirmation), 9/29 calibration (40-50% on confirmed break with full stack), payoff-capped Underweight pattern corrections, and prior NaN-telemetry process failure with explicit price/fundamental triggers logged for post-hoc P&L capture.
| Position | Action |
|---|---|
| Confirmed 200 SMA break with MACD bearish crossover and deteriorating fundamentals | Trim 35-40% at market (~$86), reducing position to 60-70% of benchmark weight |
| Support zone holds and mean-reversion occurs | Retain 60-65% core for dividend carry and Q2 FY27 catalyst participation |
| Confirmed close below $84 on volume >12M | Exit remaining position, downgrade to Sell, target $78-80 |
| Support zone holds but thesis weakens on Q2 FY27 fundamentals | Exit remaining position if revenue <+5% OR margin <18% |
Medtronic is a rare GARP setup: a world-class compounder with accelerating fundamentals (+41% net income growth), multiple new product cycles re-accelerating simultaneously, trading at a 30-40% valuation discount to peers while macro conditions (Fed on hold, defensive rotation, low recession risk) create a perfect tailwind for dividend-paying healthcare names.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $88.38 | bearish |
| close_50_sma | $89.17 | bearish |
| close_200_sma | $87.19 | neutral |
| macd | −0.70 | bearish |
| macds | −0.001 | bearish |
| macdh | −0.70 | bearish |
| rsi | 38.26 | bearish |
| atr | $2.03 | neutral |
Support: 87.19 · 85.9 · 84 · 85 | Resistance: 94.72 · 90.31 · 89.17 · 88.38
MDT exhibits a clear bearish technical setup with price ($86.44) below both the 10 EMA ($88.38) and 50 SMA ($89.17), a confirmed MACD bearish crossover with accelerating histogram (−0.70), and RSI at 38.26 still above the 30 oversold threshold indicating room to fall. The 200 SMA ($87.19) represents the critical long-term support line, while the lower Bollinger Band at $85.90 is the key near-term support to watch. Volume has surged to ~3× normal (29.28M on 10/01), confirming an institutional distribution pattern. The death cross (50 SMA crossing below 200 SMA) is not yet triggered but is a realistic scenario over the coming weeks if price weakness persists.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Revenue >+8% organic (ex-M&A) AND op margin >19.5%
Then: Add 10-15% position, bear thesis disproven
MDT trades at 30-40% valuation discount to med-tech peers
↩ rebuts: “Bear claim that stock is overvalued or range-bound”
EV: +$27% to ~$110+ (mean reversion to 17x forward P/E on FY28 consensus EPS), plus 3.3% dividend yield and ~$1B annual buybacks · concedes: MACD confirmed bearish crossover (lagging indicator at major support, not trend initiation); Death cross possible as 50 SMA ($89.17) converges on 200 SMA ($87.19); Stock is range-bound near support without immediate catalyst; Goodwill of $43B exists (industry structure, not company-specific risk per bull)
Medtronic at $86 is catching a falling knife at a 200-day SMA breakdown; the "inflection" is a low-base comp artifact, forward P/E embeds unrealistic growth, technicals are confirmed bearish with a death cross loading, FCF is rolling over, goodwill risk is 4-10x peers, and the risk/reward is asymmetric to the downside with $80-84 retest more likely than $93 retest.
EV: -$6 to $0 (from $86.50 entry to $80-86 zone); realistic target $80-84 before $93 retest · concedes: Q1 FY27 did show revenue and EPS growth relative to depressed prior-year comp; Dividend of 3.3% is real and currently covered at ~1.5x; Hugo, MiniMed 780G, and Affera PFA represent genuine product opportunities; November earnings could re-rate the stock if Q1 FY27 strength sustains; Short squeeze risk on any positive macro surprise or bullish print exists given defensive positioning and 3.3% yield; Confident bull case could trigger if 50 SMA at $89.17 is reclaimed with MACD histogram turning positive
→ vs conservative: The conservative $88 stop from the technical report is giving back all the profit and misses the asymmetric risk setup
→ vs neutral: Waiting for $85.90 to confirm is textbook analysis paralysis; by the time evidence is undeniable, the trade is over; entry moves 400-500 basis points against you
→ vs neutral: The defensive bid theory is being rejected by price action itself—MDT is selling off on 3x volume while broader tape is supported
Market Cap
$110.5B
P/E TTM
21.28x
Forward P/E
13.48x
PEG Ratio
1.55
Price/Book
2.20x
EV/EBITDA (implied)
~13x
Dividend Yield
3.33%
Beta
0.574
52-Week Range
$73.31 – $106.33
50D MA
$89.83
200D MA
$88.71
Revenue TTM
$37.54B
Gross Profit TTM
$24.50B
Gross Margin
65.3%
EBITDA TTM
$10.41B
Operating Income TTM
~$7.3B
Net Income TTM
$5.23B
FCF TTM
$5.41B
ROE
10.65%
ROA
5.12%
Q1 FY27 Revenue
$9,756M
Q1 FY27 Net Income
$1,479M
Q1 FY27 Diluted EPS
$1.14
Q1 FY27 Operating Margin
18.8%
Total Assets
$93.31B
Total Equity
$50.23B
Total Debt
$28.15B
Cash + ST Investments
$8.82B
Net Debt
$26.41B
Working Capital
$12.59B
Current Ratio
2.07x
Goodwill
$43.19B
Net Tangible Assets
-$3.19B
Interest Coverage
~10x
Net Debt/EBITDA
~2.5x
D/E
55.4%
FCF (TTM)
$5.41B
Dividend Coverage (FCF)
1.5x
Q1 FY27 Operating CF
$1,793M
Q1 FY27 CapEx
$503M
Q1 FY27 FCF
$1,290M
Q1 FY27 Dividends
$921M
Q1 FY27 Buybacks
$267M
Strengths
Concerns
Medtronic is a high-quality, defensive large-cap medical device company trading at an attractive forward P/E of 13.48x with a credible growth re-acceleration story demonstrated by Q1 FY27 revenue up 13.7% YoY and net income up 41.3% YoY; the combination of best-in-class 65.3% gross margin, $5.41B TTM FCF, 3.33% dividend yield, and low 0.57 beta makes it attractive for income and defensive investors, though near-term the stock is range-bound and needs Q2 FY27 results to confirm the inflection before breaking out of its $73-$106 range.
Macro: The dominant macro signal is a Fed on hold with 96% Polymarket-implied probability of zero rate cuts in 2026 ($8.7M volume, down 0.3pp WoW). Treasury yields are easing following a soft September 2026 jobs report, supportive for duration-sensitive equities and MDT's long-duration cash flows. Recession odds are low at 8% for US by year-end 2026 (down 2pp WoW), with the labor weakness being read as normalization rather than deterioration. However, Iran-driven geopolitical escalation is pushing energy and commodity prices higher—a supply-side inflation impulse that creates mixed signals (modest margin pressure vs. defensive bid). The macro combination—policy on hold, no recession scare, and easing yields—is neutral-to-mildly-positive for high-quality defensive equities and historically constructive for healthcare dividends.